Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ilypsa has completed enrollment of the phase II clinical trial of a kidney drug in the US.
Subscribe to our email newsletter
ILY101 is a phosphate binding agent for the treatment of hyperphosphatemia, a serious complication in patients with kidney disease on dialysis.
The ILY101 phase II trial is a dose-ranging study and is designed to examine the efficacy and tolerability of ILY101 in patients with kidney disease with hyperphosphatemia on hemodialysis.
“This rapid progress in the clinical development of ILY101 exemplifies the short development timelines inherent to our technology, as we have gone from IND to completion of ILY101 phase II enrollment in just one year,” said Jay Shepard, president and CEO of Ilypsa.